Further Information
epilepsy, progressive myoclonus type 2, Lafora disease (laforin), laforin, EPM2A, epilepsy, progressive myoclonus type 2A, Lafora disease (laforin), EPM2, MELF
Peptide ELISA: antibody detection limit dilution 1:16000.Western Blot:Approx. 38kDa band observed in Human Brain (Cerebellum) lysates (calculated MW of 37.2kDa according to NP_005661.1). Recommended concentration: 0.1-0.3ug/ml. Primary incubation was 1 hour.Immunohistochemistry:Paraffin embedded Human Brain (Cerebellum) and Heart. Recommended concentration: 2.5ug/ml.
- Mittal S, Dubey D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genet. 2007 Apr 1;16(7):753-62. Epub 2007 Mar 2.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20?C. Minimize freezing and thawing.
500 ug/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Expected Species Reactivity based on sequence homology: Mouse, Rat, Dog, Cow
The immunogen for this antibody is: C-EATGHTNEMKHTTD
7957
epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)
EPM2A
Homo sapiens
Liquid
NP_005661.1
11321613
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Homeostasis ,Neuroscience
This antibody is expected to recognize isoform a (NP_005661.1) only.
B3EWF7